Kathryn McLerran
Family Medicine · Guthrie, OKNPI 1205216157
Payments from drug & device makers
Across 179 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$514
- Novo Nordisk$444
- Lilly USA, LLC$363
- AbbVie$289
- GSK$193
- Amarin Pharma, Inc.$140
- plus $926 from 24 others
What the payments were for
- Food & beverage$2,869100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 34 | $514 |
| Novo Nordisk | 29 | $444 |
| Lilly USA, LLC | 24 | $363 |
| AbbVie(2 entities) | 16 | $289 |
| GSK | 13 | $193 |
| Amarin Pharma, Inc. | 8 | $140 |
| Merck | 9 | $124 |
| AstraZeneca(2 entities) | 6 | $94 |
| Boehringer Ingelheim | 5 | $75 |
| Biogen | 4 | $60 |
| Exact Sciences | 3 | $59 |
| Mylan Specialty L.p. | 3 | $58 |
| Nabriva Therapeutics, PLC | 3 | $57 |
| Abbott | 3 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Bayer | 2 | $32 |
| Amgen | 2 | $30 |
| Lundbeck LLC | 1 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| Genentech USA, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Medtronic | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
How this compares
$2,869 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $70,063 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $69,232 |
| JardianceEmpagliflozin | 54 | $67,291 |
| EliquisApixaban | 33 | $55,002 |
| MounjaroTirzepatide | 27 | $36,988 |
| Spiriva RespimatTiotropium Bromide | 35 | $35,577 |
| TrulicityDulaglutide | 21 | $33,341 |
| RybelsusSemaglutide | 22 | $31,932 |
| FarxigaDapagliflozin Propanediol | 20 | $29,239 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $28,520 |
| VraylarCariprazine Hcl | 19 | $25,841 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $23,851 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 23 | $18,396 |
| MyrbetriqMirabegron | 20 | $17,095 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $16,075 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Synjardy Xr | $75 | $145,115142 claims |
| Novo NordiskOzempic, Rybelsus | $444 | $101,99567 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $193 | $92,48199 claims |
| Lilly USA, LLCMounjaro, Trulicity | $363 | $70,32948 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $94 | $57,76044 claims |
| PfizerEliquis | $514 | $55,00233 claims |
| AbbVieVraylar, Ubrelvy | $289 | $37,51031 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $17,09520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Guthrie
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.